China Wants to Patent Gilead’s Experimental Coronavirus Drug
- Wuhan’s virology institute has applied for remdesivir’s patent
- Gilead said human trials on the drug have begun in China
This article is for subscribers only.
Chinese researchers have applied for a national patent on an experimental Gilead Sciences Inc. drug that they believe might fight the novel coronavirus .
The Wuhan Institute of Virology -- based in the Chinese city at the center of the epidemic -- has applied for a patent in China for the use of the antiviral drug, known as remdesivir, in treating the ailment. The application was made on Jan. 21 together with a military academy, according to a Feb. 4 statement on the institute’s website.